Swedish Cohort: HPV Vaccination Linked to Sustained Protection up to 18 years

A recent report describes a nationwide, register-based analysis from Sweden that followed girls and women through 31 Dec 2023 and examined associations between human papillomavirus (HPV) vaccination history and subsequent invasive cervical cancer risk. Results are framed around two themes: differences by age at vaccination and whether protection appeared durable over long follow-up.

The investigators drew on girls and women born from 1985 to 2001 and living in Sweden, with follow-up spanning 1 Jan 2006 to 31 Dec 2023. In this cohort of 926,362 individuals, 365,502 (40%) received at least one dose of the quadrivalent HPV vaccine. Across follow-up, the article reports 930 cases of invasive cervical cancer—97 among vaccinated individuals and 833 among those unvaccinated. The comparison emphasized in the report is the observed difference in incidence/risk between vaccinated and unvaccinated participants within this nationwide cohort.

Age at vaccination was presented as a key stratifier in the investigators’ estimates. According to the summary, vaccination before age 17 was associated with a 79% lower risk of invasive cervical cancer compared with being unvaccinated. Vaccination at age 17 or older was also reported as being associated with lower risk versus the unvaccinated group, but with a smaller relative reduction overall (37% lower risk). The authors’ presentation of these strata centered on timing of vaccination as an explanatory dimension of the observed risk pattern.

The report also summarized estimates by time since vaccination, highlighting multiple post-vaccination intervals. For those vaccinated at age 17 or older, the summary reports a 46% lower risk 10–12 years after vaccination and a 77% lower risk 13–15 years after vaccination compared with the unvaccinated group; for those vaccinated before age 17, it reports sustained protection, including a 77% lower risk in the 13–15-year interval. In the investigators’ wording as relayed in the article, there was “no indication” of waning protection through as long as 18 years of follow-up. Durability over extended observation was described as a central longitudinal finding.

Alongside individual-level comparisons, the summary describes population-level declines in invasive cervical cancer cases across later birth cohorts. It reports the highest rates among women born in 1985–1988, reaching around 250 cases per 100,000 by age 38, with progressively lower rates in later cohorts and substantially lower rates for those born in 1999–2001 (reported as four per 100,000 by age 24). The authors also outlined limitations typical of register-based observational analyses, including possible misclassification of vaccination status, the potential for healthy volunteer bias, and unmeasured confounding factors such as smoking and sexual activity. The report closes by noting that the authors conclude the findings support global strategies to eliminate cervical cancer as a public health problem through high routine HPV vaccination coverage, while acknowledging the study’s observational caveats.

Key Takeaways:

• In a Swedish register-based cohort followed from 2006 to 2023, invasive cervical cancer occurrence was compared between vaccinated and unvaccinated individuals and was reported using nationwide counts.
• Lower invasive cervical cancer risk was reported in association with HPV vaccination, with a larger relative reduction described for vaccination before age 17 than for vaccination at age 17 or older.
• Time-since-vaccination estimates were reported through long follow-up, with the authors noting no indication of waning up to 18 years and describing limitations consistent with observational data.